Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PainChek Ltd ( (AU:PCK) ) has provided an update.
PainChek Ltd has issued a total of 325,000 unquoted options under its employee incentive scheme, with exercise prices of $0.04 and $0.0356 and expiries in March and February 2030 respectively. The move underscores the company’s use of long-dated equity incentives to align staff interests with shareholders and support retention as it executes its growth and product commercialisation strategy.
The new options, which are not intended to be quoted on the ASX, expand PainChek’s pool of employee equity and may contribute to future dilution if exercised. For stakeholders, this structure signals continued investment in human capital while preserving cash, a common approach among growth-stage healthtech firms seeking to balance funding constraints with the need to attract and retain specialised talent.
The most recent analyst rating on (AU:PCK) stock is a Sell with a A$0.20 price target. To see the full list of analyst forecasts on PainChek Ltd stock, see the AU:PCK Stock Forecast page.
More about PainChek Ltd
PainChek Ltd is a healthcare technology company listed on the ASX that develops and commercialises digital tools for pain assessment. Its products are focused on improving pain monitoring and management, particularly in clinical and care settings, by leveraging technology-enabled solutions for more accurate and consistent evaluation.
Average Trading Volume: 163,070
Technical Sentiment Signal: Sell
Current Market Cap: A$43.89M
See more data about PCK stock on TipRanks’ Stock Analysis page.